Gene therapy offers tremendous promise for the treatment of both rare and common diseases. Despite initial successes, growth of the field has been slower than predicted. By leveraging characteristics that products have in common whenever possible, by intensely focusing on manufacturing, by maximally employing expedited development pathways, and by fostering international collaboration, FDA hopes to accelerate the pace of bringing advances to the benefit of patients.
Director, Center for Biologics Evaluation and Research,
You must be logged in and own this session in order to